Nattokinase: Blood Thinning, Clot Prevention, and Circulation

Nattokinase is a serine protease enzyme extracted from natto, a traditional Japanese fermented soybean food. Unlike most supplements that support cardiovascular health indirectly through antioxidant or anti-inflammatory mechanisms, nattokinase acts directly on the blood coagulation system — specifically by dissolving fibrin, the protein scaffold of blood clots. This gives it a pharmacologically relevant mechanism that demands both serious consideration and careful attention to safety.

What Nattokinase Does in the Body

Nattokinase cleaves fibrin, the insoluble protein that forms the structural mesh of blood clots. This fibrinolytic activity is measurable and comparable, in some studies, to the early stages of the body's own clot-dissolving system. It also activates endogenous plasminogen activators — proteins the body uses to break down fibrin — and inhibits plasminogen activator inhibitor-1 (PAI-1), which would otherwise suppress clot dissolution.

In healthy circulation, this translates to reduced blood viscosity, improved microvascular flow, and lower fibrinogen levels. Fibrinogen is an independent cardiovascular risk factor — elevated levels predict cardiovascular events beyond LDL or blood pressure — and nattokinase's consistent ability to reduce fibrinogen is one of its more clinically meaningful effects.

Hypertension: More Than Just Clot Prevention

Several clinical trials have examined nattokinase for blood pressure, yielding surprisingly strong results. An 8-week double-blind RCT in 73 hypertensive Japanese adults found that nattokinase supplementation (2,000 FU/day) reduced systolic blood pressure by 5.5 mmHg and diastolic by 2.8 mmHg compared to placebo. A subgroup analysis showed greater effects in those not on antihypertensive medications.

The mechanism for blood pressure reduction is thought to involve ACE inhibition — nattokinase contains peptide fragments with ACE-inhibitor-like activity — as well as improved microvascular compliance from reduced blood viscosity. These blood pressure effects make nattokinase a dual-purpose supplement for thrombotic risk and hypertension management.

Atherosclerosis and Plaque

A 26-week RCT published in Scientific Reports found that daily nattokinase supplementation (6,000 FU/day) significantly reduced carotid intima-media thickness (CIMT) — a marker of subclinical atherosclerosis — more effectively than statin therapy in a low-to-moderate risk population. This is a provocative finding that requires replication but aligns with nattokinase's ability to reduce fibrinogen, platelet aggregation, and inflammation.

Atherosclerotic plaques contain a fibrin-rich framework, and some researchers hypothesize that fibrinolytic activity can slowly dissolve or reduce the fibrin component of plaques. Whether this translates to clinical event reduction requires larger long-term trials.

Dosing and Units

Nattokinase potency is measured in fibrinolytic units (FU), not milligrams, because the enzyme's activity — not mass — is what matters. Typical doses in clinical trials range from 2,000-6,000 FU/day. Standard commercial supplements provide 2,000 FU per capsule. For blood pressure support, 2,000 FU/day appears effective; for more aggressive thrombotic risk management, 4,000-6,000 FU/day has been used.

Nattokinase should be taken on an empty stomach for best absorption. It is typically sourced from natto and does not contain vitamin K2 in supplemental nattokinase products (K2 is present in whole natto but removed during enzyme isolation — important for people avoiding K2 due to warfarin therapy).

Drug Interactions: A Critical Consideration

Nattokinase's blood-thinning activity creates significant interaction risk with anticoagulant and antiplatelet medications. Combining nattokinase with warfarin, heparin, apixaban, rivaroxaban, or aspirin can substantially increase bleeding risk. This is not theoretical — case reports of bleeding events exist with concurrent use.

Any person on anticoagulant therapy must discuss nattokinase with their physician before use. People scheduled for surgery should stop nattokinase at least 1-2 weeks beforehand. Similarly, people with known clotting disorders, a history of hemorrhagic stroke, or high bleeding risk should avoid nattokinase without medical supervision.

FAQ

Q: Is nattokinase as effective as blood thinning medications?

No. Pharmaceutical anticoagulants provide more potent, predictable, and better-monitored anticoagulation than nattokinase. Nattokinase is appropriate for general thrombotic risk reduction in people without conditions requiring pharmaceutical anticoagulation.

Q: Can I take nattokinase if I have had a blood clot?

Discuss with your physician. People with a history of deep vein thrombosis or pulmonary embolism are typically on pharmaceutical anticoagulants, and nattokinase should not replace these. As an adjunct, supervision is essential.

Q: Does nattokinase contain vitamin K?

Supplemental nattokinase (the purified enzyme) does not contain significant vitamin K. Whole natto is very high in vitamin K2. Warfarin users can generally take purified nattokinase but must verify K2 content with the specific product.

Q: How does nattokinase compare to serrapeptase?

Both are proteolytic enzymes with anti-inflammatory and fibrinolytic properties, but nattokinase has much stronger clinical evidence. Serrapeptase's evidence is primarily limited to post-surgical inflammation and ENT applications.

Related Articles

• Bergamot Polyphenols for Cholesterol and Blood Sugar
• CoQ10 for Heart Health: From Deficiency to Clinical Trials
• Ginkgo Biloba for Circulation and Brain Blood Flow
• Hawthorn Berry for Heart Health: Evidence and Use
• Hibiscus Tea and Supplements for Blood Pressure: The Evidence

Track your supplements in Optimize.